Prostate Cancer News Today

    Skip to content
    • Home
    • About Prostate Cancer
      • About the Prostate
        • Diseases of the Prostate
      • Prostate Cancer Causes
      • Prostate Cancer Symptoms
        • Blood in Urine
        • Erectile Dysfunction
        • Pain
        • Urinary Problems
        • Weakness or Numbness
      • Prostate Cancer Diagnosis
      • Prostate Cancer Stages
      • Prostate Cancer Prevention
      • Prostate Cancer Statistics
      • Living With Prostate Cancer
    • Treatment
      • About Prostate Cancer Trials
      • Biologic Therapy
      • Bisphosphonate Therapy
      • Bone-directed Treatment
      • Cabazitaxel
      • Carboplatin
      • Casodex (bicalutamide)
      • Chemotherapy
      • Complementary and Alternative Medicine (CAM)
      • Cryotherapy
      • Degarelix
      • Docetaxel
      • Doxorubicin
      • Enzalutamide
      • Erleada (Apalutamide)
      • Estramustine
      • Etoposide
      • Flutamide
      • Goserelin Acetate
      • Hormone Therapy
      • Mitoxantrone
      • Orchiectomy
      • Paclitaxel
      • Radical Prostatectomy
      • Radiation Therapy
        • Radium 223 Dichloride
      • Sipuleucel-T
      • Transurethral Resection of the Prostate (TURP)
      • Vinblastine
      • Vinorelbine
      • Watchful Waiting
      • Zytiga (abiraterone acetate)
    • Columns
      • Living & Loving with Prostate Cancer
      • Rick’s Prostate Column
    • COVID-19 Info
      • COVID-19 Updates

    Men Willing to Pay Up to $2,000 For Better Prostate Cancer Test, Study Shows

    April 27, 2017
    Magdalena Kegelby Magdalena Kegel

    In News.

    Men Willing to Pay Up to $2,000 For Better Prostate Cancer Test, Study Shows
    Click here to subscribe to the Prostate Cancer News Today Newsletter!
    0
    (0)

    Men would be willing to pay up to $2,000 of their own money to get a more accurate test to detect — or rule out — prostate cancer.

    This was the outcome of a study that examined how men viewed a technique that — although available — is rarely covered by health insurance plans.

    The research, “Examining patient’s willingness-to-pay for MRI guided prostate biopsy: Implications in the era of health savings accounts,” was published in the journal Urology Practice. It was a collaborative effort of Loyola Medicine and Loyola University Chicago’s Quinlan School of Business and Stritch School of Medicine.

    MR-US prostate biopsy is the name of the pricey method. It combines advanced imaging with a traditional prostate biopsy.

    Physicians first do a magnetic resonance imaging (MRI) scan of the prostate. The images are fused with ultrasound images to create a three-dimensional view of the prostate. A physician uses the 3D view doing a biopsy to guide a biopsy needle to suspicious-looking lesions.

    A standard biopsy involves a physician taking 12 samples across the prostate. If a tumor is not in the areas, it’s likely to be missed.

    Although the imaging-biopsy combo procedure is more accurate, it is not always covered by insurance. And it costs between $700 and $1,570 more than a standard biopsy, depending on the clinic.

    To understand how men view the combo technique, and what they would be willing to pay for it, a research team surveyed 202 men at a urology clinic.

    They asked the men to imagine that they needed a prostate cancer biopsy, and had $2,000 in a health savings account.

    In the United States, people with high-deductible insurance plans can open such an account. It works like a normal savings account, but savings are tax-deductible. And the money can be spent only on healthcare.

    The men said they were prepared to pay $1,598 more for a biopsy that increased from 43 percent to 51 percent the likelihood that doctors would detect a prostate cancer. The figures mirror the difference doctors see between standard and MR-US biopsies.

    If a biopsy could increase from 70% to 90% the chance of ruling out cancer when none is there, the men would pay $2,034. Again, the difference reflects that seen between the two biopsy types.

    In contrast, the men were not prepared to pay extra for a biopsy that would increase the chance of detecting only high-risk cancer.

    “An enhanced understanding of patient preferences, and the monetary value that they place on these preferences, will be imperative to understand as healthcare delivery rapidly moves towards a consumer-driven era,” the researchers said in a press release.

    Since health savings accounts are becoming more common, the findings may be useful when urologists discuss options with their patients.

    “The value placed on MR-US prostate biopsy is particularly useful when urologists are counseling patients with a health savings account and/or patients whose insurance does not cover MR-US prostate biopsy,” researchers wrote.

    Print This Page

    How useful was this post?

    Click on a star to rate it!

    Average rating 0 / 5. Vote count: 0

    No votes so far! Be the first to rate this post.

    As you found this post useful...

    Follow us on social media!

    We are sorry that this post was not useful for you!

    Let us improve this post!

    Tell us how we can improve this post?

    Tagged health savings account, imaging, insurance, MR-US prostate biopsy, prostate biopsy.

    Post navigation

    metastatic prostate cancer studyPrevious: Assay Shown to Help Detect Prostate Cancer Patients at Risk of Metastasis
    futility of PSA worryNext:The Futility of Worrying About Cancer

    Create your own user feedback survey

    Recent Posts

    • dogs

      Cancer-sniffing Dogs May Help Train Robot Noses to Detect Tumors Early

      February 25, 2021

    • Prolaris test and ADT

      Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

      February 23, 2021

    • Erleada trial results

      Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

      February 18, 2021

    Featured Posts

    FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

    June 30, 2020

    Orgovyx available in U.S.

    Relugolix Granted FDA Priority Review as New Treatment Type

    June 25, 2020

    relugolix granted FDA priority review

    U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population

    June 9, 2020

    genetic screening
    Visit Prostate Cancer News Today's profile on Pinterest.

    PC News Today

    BioNews Services, LLC
    3 W Garden St
    Suite 700
    Pensacola, FL 32502
    Email: [email protected]
    Phone: +1-800-936-1363
    • Subscription Support
    • Publishing Team
    • Leadership
    • Our Values
    • Corrections Policy
    • Contact Us
    • Privacy Policy
    • Terms of Service

    Disclaimer:

    Prostate Cancer News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2021 Proudly powered by WordPress | Binder PRO Theme by QuadroIdeas